Phase 1b Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide or Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-002)
The purpose of this study is to determine the side effects, good and/or bad, and the highest dose of an investigational drug called ZEN003694 when given in combination with enzalutamide or abiraterone, FDA approved treatments for metastatic castration resistant prostate cancer, in participants with metastatic castration resistant prostate cancer. Another purpose of the study is to determine how the body processes and gets rid of the study drug.
Metastatic castration resistant prostate cancer (mCRPC)
- Subjects should have metastatic castration-resistant prostate cancer
- Subjects should have recent disease progression after treatment with FDA approved anti-androgen therapy (abiraterone or enzalutamide or apalutamide)
- Subjects should not have previous treatment with chemotherapy in metastatic castration-resistant setting
- Subjects should not have any history of brain metastasis or conditions predisposing to seizure
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will receive the investigational drug and either enzalutamide or abiraterone until their cancer gets worse or they experience unacceptable side effects. There will be one final safety visit 30 days after discontinuation of the study drugs.
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Zenith Epigenetics Corp.